Fosun-backed Gland Pharma readies Rp65bn IPO
Gland Pharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, has set the final terms for its Rp64.8bn ($866.5m) IPO in India.
Gland Pharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, has set the final terms for its Rp64.8bn ($866.5m) IPO in India.
Chinese biopharmaceutical firm RemeGen has raised HK$3.99bn ($514.7m) after pricing its IPO at the top of the marketed range, according to a source familiar with the matter.
The Shanghai bourse stunned the market on Tuesday after halting Ant Group’s $34bn IPO, a deal which was set to be the largest listing in history. The extraordinary move, likely spurred by comments from Ant’s
South Korean game developer Kakao Games is set to list in September for up to W340bn ($284.8m), reviving the deal two years after dropping its initial IPO plans.
Thai express delivery company Kerry Express launched its IPO this week, aiming to raise up to Bt8.4bn ($278.2m) in proceeds.
The volatility has caused some M&A and initial public offering deals to be put on hold
Fast food franchise operator Yum China Holdings is cooking a multi-billion-dollar secondary offering in Hong Kong. It is the latest deal in a growing trend that bankers expect will bring more US-listed Chinese companies to
In this round-up, Chinese financial institutions are given another year to comply with new asset management rules due to the Covid-19 pandemic, Luckin Coffee will be punished by the Ministry of Finance for inflating its
City broker hires former Goldman analyst to lead new team helping companies raise private money amid a slump in IPOs
Posted by Ramana Nanda (Harvard Business School), Sampsa Samila (IESE Business School), and Olav Sorenson (Yale University), on Wednesday, February 26, 2020 Editor's Note: Ramana Nanda is the Sarofim-Rock Professor of Business Administration at Harvard
More than 70% of 90 IPOs backed by buyouts between 2010 and 2014 underperformed
Carlyle has already delayed the US IPO of chemicals manufacturer Atotech
Flotations in the City fell by more than half to 35 last year. With fewer joining than leaving, the number of public companies continues to fall
If no agreement can be reached with a bidder, an IPO remains an option, Thyssenkrupp said
China Resources Mixc Lifestyle Services, the property management business of state-owned developer China Resources Land, is set to price its HK$12.3bn ($1.58bn) Hong Kong IPO at the top end of guidance.
JD Health International has bagged HK$27bn ($3.5bn) after sealing its IPO at the top end of the marketed range, following a flood of global investor demand.
Chinese developer Sunkwan Properties has kicked off its IPO roadshow. It is aiming to raise up to HK$1.25bn ($161.2m).
South Korea’s Bit Hit Entertainment, the manager of K-pop boy band BTS, is set to launch an IPO worth up to W962.6bn ($811.7m) later this month.
Hong Kong’s IPO market had one of its busiest periods in years this week, with more than 10 live deals vying for investor attention. But bankers in the city are concerned by the ECM market’s
The company set the price of its initial public offering on the London Stock Exchange at 240 pence each
